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Abstract
Background: Few data are available on prescriber adherence to tuberculosis (TB) treatment guidelines. In
particular, excessively long treatment carries a risk of avoidable adverse effects and represents a waste of
healthcare resources. We examined factors potentially associated with excessively long treatment.
Methods: We reviewed the medical records of patients diagnosed with TB in 2004 in the eastern Paris region.
Sociodemographic and clinical factors associated with excessively long treatment were identified by logistic
regression analyses. Based on contemporary guidelines, excessively long treatment was defined as more than 6
months of a four-drug regimen for thoracic TB with full sensitive strains, and more than 12 months for patients
with extrathoracic TB.
Results: Analyses concerned 478 patients with a median age of 36.0 ± 13.5 years, of whom 48% were living in
precarious conditions (i.e. poor living conditions and/or no health insurance), 80% were born abroad, and 17%
were HIV-seropositive. TB was restricted to the chest in 279 patients (isolated pulmonary, pleuropulmonary, and
isolated pleural TB in 245, 13, and 21 patients, respectively), exclusively extrathoracic in 115 patients, and mixed in
the remaining 84 patients. Treatment was prescribed by a chest specialist in 211 cases (44.1%) and 295 patients
(61.7%) were managed in a single institution. The treatment duration complied with contemporary guidelines in
316 cases (66.1%) and was excessively long in 162 cases (33.9%). The median duration of excessively long
treatment was 313 days (IQR: 272-412). In multivariate analysis, isolated thoracic TB, previous TB, HIV infection, a
prescriber other than a chest specialist, and management in more than one healthcare center during treatment
were independently associated with excessively lengthy treatment.
Conclusion: One-third of TB patients received excessively long treatment, reflecting inadequate awareness of
management guidelines or unwillingness to implement them.
Background
Many practitioners fail to comply with clinical practice
guidelines[1]. In the United States for example, one
study showed that a quarter of physicians prescribed
excessively lengthy tuberculosis (TB) therapy, even
though many of them were aware of the relevant guide-
lines[2]. Likewise, a French study based on a self-ques-
tionnaire completed by practitioners compared actual
practices with TB management guidelines[3]. These
practitioners declared that they frequently prescribed
lengthy treatments to patients with extrapulmonary TB.
Such excessive treatment carries a risk of avoidable
adverse effects and represents a waste of healthcare
resources. Here we examined the frequency of and risk
factors for excessively lengthy TB therapy among
patients diagnosed in the eastern Paris region of France
in 2004.
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Methods
Patients
All patients diagnosed with Mycobacterium tuberculosis
culture-positive TB (thoracic, pulmonary or pleural,
and/or extrathoracic) between 1 January and 31 Decem-
ber 2004 in the eastern Paris region were considered for
inclusion in this retrospective study. Sociodemographic
and clinical data were collected from the medical files,
as previously described[4].
We excluded patients whose treatment period was not
known, patients with multidrug-resistant TB (for whom
the recommended treatment period is at least 18
months), and patients whose treatment was too short
(less than 6 months of a four-drug regimen or of a
three-drug regimen including pyrazinamide, or less than
9 months of a three-drug regimen without pyrazina-
mide). These latter patients are described in detail else-
where, along with factors associated with excessively
short treatment[4].
The remaining patients were divided into those whose
treatment period complied with contemporary guide-
lines and those whose treatment was excessively lengthy,
taking into account the drug regimen and the form of
TB.
Treatment duration according to international and
French guidelines
WHO guidelines contemporary to the study recom-
mended a 6-month four-drug regimen for newly diag-
nosed extrapulmonary and pulmonary TB[5,6]. The
corresponding French guidelines specified that treat-
ment for minor forms of extrapulmonary TB should be
as long as that for pulmonary TB, but a 9- to 12-month
course could be prescribed for severe extrapulmonary or
neuro-meningeal TB[7]. Based on the French guidelines,
we considered that a 6-month four-drug regimen for
pulmonary-TB and a 6- to 12-month course for extra-
pulmonary TB were in keeping with guidelines. In addi-
tion, 6 months of a three-drug regimen including
rifampicin, isoniazid and pyrazinamide for patients with
fully sensitive strains, and 9 months of a three-drug
regimen without pyrazinamide were also considered to
be in keeping with guidelines. In case of resistance to
isoniazid, isoniazid was replaced by ethambutol and
treatment could be extended to 12 months[5-7]. All
other patients with no prior history of TB were consid-
ered to have received excessively lengthy therapy.
In 2003, WHO recommended an 8-month retreatment
regimen with first-line drugs while awaiting drug sus-
ceptibility testing (DST) results for patients who had
relapsed[5]. In France, DST being readily available and
rates of MDR-TB being low, contemporary guidelines
recommended prompt empirical therapy with first-line
drugs while waiting for the results of DST: longer treat-
ment for previously treated patients was not routinely
recommended[7]. Based on French guidelines, we con-
sidered that a 6-month course of standard treatment
was in keeping with guidelines in patients with fully sen-
sitive strains who had previously been treated for TB.
As treatments rarely last precisely the recommended
period in practice, periods of 167-213 days were consid-
ered to correspond to six months, 213-274 days to 6-9
months, 274-365 days to 12 months, and 366-543 days
to 18 months.
The study protocol was approved by the Saint Antoine
Teaching Hospital Ethics Committee.
Statistical analysis
We analyzed sociodemographic and clinical characteris-
tics (age, sex, place of birth, socioeconomic status, pre-
vious TB, main comorbidities, form of TB, and drug
resistance) and TB management modalities (specialty of
the prescribing physician, the healthcare center(s) where
follow-up took place, the type and number of healthcare
structures involved in the management of individual
patients, use of directly observed therapy (DOT), and
computerized patient follow-up). A precarious socio-
economical situation was defined as the absence of
health insurance and/or poor living conditions (e.g.
homelessness, living in a migrant shelter, or living in a
hostel). The number of healthcare institutions managing
a given patient was defined as the number of different
physicians or healthcare structures involved in the
patient’s follow-up (e.g. general practitioner, hospital
department or convalescence unit).
Stata software version 8 (StataCorp LP, TX) was used
for all analyses, and significance was assumed at p <
0.05. Fisher’s exact test was used to identify significant
differences between categorical variables, and the Wil-
coxon-Mann-Whitney test was used for continuous vari-
ables. Logistic regression analysis was used to identify
predictors of excessively lengthy therapy. All variables
with p values ≤ 0.20 in univariate analysis were included
in multivariate analysis, with backward elimination of
the variables.
Results
A total of 721 cases of bacteriologically confirmed TB
were diagnosed in the eastern Paris region in 2004. The
medical files of 97 patients (13.4%) did not include the
treatment duration follow-up data, or could not be
found despite an active search, and 15 patients (2.1%)
had a post-mortem diagnosis or were immediately lost
to follow-up and therefore received no treatment (Figure
1). Ten patients had multidrug-resistant TB, and 121
patients were treated for less than 6 months. The
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reasons for excessively short treatment were loss to fol-
low-up (65 patients, 53.7%), treatment interruption (18
patients, 14.9%), transfer to another healthcare structure
(14 patients, 11.6%) and death (24 patients, 19.8%).
This analysis focused solely on the remaining 478
patients, 316 (66.1%) of whom had a treatment duration
in keeping with contemporary guidelines, and 162
(33.9%) received excessively lengthy therapy.
These 478 patients were managed in 19 healthcare
structures, comprising 10 university hospitals, three gen-
eral hospitals, a detention center, and five welfare centers,
in respectively 68.7%, 21.5%, 1.1% and 8.7% of cases.
Median age was 36.0 ± 13.5 years, 68% of patients
were male and 80% were born abroad. The main socio-
demographic, clinical and management characteristics of
the 478 patients included in the study are summarized
in Table 1 according to the treatment duration (accord-
ing to guidelines/excessive). TB was restricted to the
chest in 279 patients (isolated pulmonary TB in 245
patients, pleuropulmonary TB in 13 patients, and iso-
lated pleural TB in 21 patients), exclusively extrathoracic
in 115 patients, and mixed in the remaining 84 patients.
The treatment durations for isolated thoracic TB and
extrathoracic TB are detailed in Table 2. Among the
279 patients with isolated thoracic TB, 107 (38.3%) had
excessively lengthy therapy; 23 of these patients were
HIV-seropositive, including a patient who received a
three-drug regimen without pyrazinamide. Fifty-five
patients with extrathoracic TB (27.6%) were treated for
excessively lengthy periods (more than 12 months).
Respectively 65.3%, 90.9% and 85.4% of patients with
nodal, osteoarticular and disseminated forms were trea-
ted for excessively lengthy periods (more than 6
months). In univariate analyses (right part of Table 1),
the following factors were associated with excessively
lengthy therapy: isolated thoracic TB (p = 0.02), HIV
seropositivity (p = 0.001), injecting drug use (p = 0.01),
alcoholism (p = 0.004), previous TB (p < 0.0001), treat-
ment by a physician other than a chest specialist (p =
0.002), and use of more than one healthcare structure
during follow-up (p = 0.01). In multivariate analysis
(Table 1), isolated thoracic TB, HIV seropositivity, pre-
vious TB, a prescriber other than a chest specialist, and
use of more than one healthcare structure during fol-
low-up remained significantly associated with excessively
lengthy treatment.
Discussion
In 2004, in the eastern Paris region of France, almost
one-third of patients diagnosed with TB were treated
for periods exceeding those recommended by contem-
porary French and WHO guidelines[5,7]. These results
are in keeping with some other recent reports. For
example, a 2004 questionnaire-based survey of 66 pre-
scribers of antituberculous treatment in France showed
that pulmonary TB was treated for an average of 6
months, miliary and nodal forms for 9 months, and oss-
eous forms for 12 months,[3] while the respondents
recommended nine months of treatment (range 6-18
months) for HIV-infected patients with pulmonary TB.
This tendency to treat for longer than recommended
has also been reported in the United States, where one
study showed that 28% of physicians exceeded the
recommended treatment period[2]. Likewise, in India,
60.2% of prescriptions were for periods longer than
necessary[8].
The main consequences of excessively lengthy treat-
ment are higher costs and more frequent dose-
10 patients with multidrug resistant TB
97 cases with medical reports unavailable or incomplete
15 patients without treatment initiation
(3 post mortem diagnoses, 12 immediately lost to follow-up) 
624 medical reports available 
721 cases of bacteriologically 
confirmed tuberculosis
478 patients included in the study
121 patients with too short a treatment duration
316 patients with a treatment duration according to guidelines
162 patients with an excessively lenghty treatment duration
Figure 1 Study profile.
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Table 1 Clinical and management characteristics of the study patients and analysis of features associated with an
excessively lengthy treatment























Previous TB 53 (11.1%) 22 (7.0%) 31 (19.1%) 315 [252-387] 3.0 [1.8-5.8] <0.0001 2.9 [1.6-5.4] 0.001
Isolated thoracic TB 279 (58.4%) 172 (54.4%) 107 (66.0%) 275 [250-311] 1.6 [1.1-2.4] 0.02 2.2 [1.4-3.5] <0.0001
HIV seropositivity 74 (16.9%) 36 (11.4%) 38 (23.5%) 361 [289-418] 2.3 [1.4-3.8] 0.001 2.5 [1.4-4.4] 0.002
Alcoholism 83 (19.4%) 42 (13.3%) 41 (25.3%) 287 [266-367] 2.0 [1.2-3.3] 0.004*** - -
Injecting drug use 10 (2.1%) 02 (0.6%) 08 (4.9%) 352 [305-419] 7.5 [1.6-35.8] 0.01*** - -
Psychiatric disorders 38 (7.9%) 23 (7.3%) 15 (9.3%) 321 [274-367] 1.2 [0.6-2.3] 0.62
Precarious situation* 210 (43.9%) 137 (43.4%) 73 (45.1%) 292 [274-407] 1.0 [0.7-1.5] 0.98
Isoniazid resistance 27 (5.6%) 17 (5.4%) 10 (6.2%) 273 [241-396] 1.1[0.5-2.6] 0.72
Management modalities
Prescriber 0.002 0.01
Chest specialist 211 (44.1) 157 (49.7%) 54 (33.3%) 274 [265-315] 1 (reference) 1 (reference)
Infectious disease specialist 171 (35.8%) 98 (31.0%) 73 (45.1%) 354 [274-427] 2.2 [1.4-3.3] 2.1 [1.3-3.4]
Other 96 (20.1%) 61 (19.3%) 35 (21.6%) 379 [287-498] 1.7 [1.0-2.8] 1.9 [1.1-3.3]
Number of institutions per patient 0.01 0.001
1 295 (61.7%) 210 (66.7%) 85 (52.8%) 282 [257-375] 1 (reference) 1 (reference)
2 152 (31.8%) 93 (29.5%) 59 (36.6%) 366 [274-448] 1.6 [1.0-2.4] 1.7 [1.1-2.7]
≥3 29 (6.5%) 12 (3.8%) 17 (10.6%) 356 [292-471] 3.5 [1.6-7.6] 4.3 [1.9-10.1]
Place of follow-up** 0.07*** -
University hospital 423 (88.5%) 274 (86.7%) 149 (92.0%) 332 [271-431] 1 (reference)
Welfare centers or other 55 (11.5%) 42 (13.3%) 13 (8.0%) 276 [273-288] 1.7 [0.9-3.4]
Directly Observed Therapy 32 (6.7%) 16 (5.1%) 16 (9.9%) 292 [275-352] 2.0 [1.0-4.2] 0.06*** - -
Computerized follow-up 145 (30.3%) 104 (34.2%) 41 (25.3%) 294 [274-367] 0.7 [0.4-1.0] 0.08*** - -
*Poor living conditions and/or no health insurance
**Main structure used by each patient
***Non significant variables in the multivariate analysis
Table 2 Treatment duration for isolated thoracic tuberculosis (TB) according to the type of treatment, and for
extrathoracic TB according to the disease location
Type of patients Treatment duration (months)
6 6-9 9-12 12-18 > 18
Isolated thoracic TB, N = 279 163 (58.4%)* 46 (16.5%) 58 (20.8%) 10 (3.6%) 2 (0.7%)
Four-drug regimen, N = 241 146 (60.6%) 30 (12.5%) 53 (22.0%) 10 (4.1%) 2 (0.8%)
Three-drug regimen without ethambutol, N = 23 14 (60.9%) 7 (30.4%) 2 (8.7%) - -
Three-drug regimen without pyrazinamide, N = 8 3 (37.5%) 2 (25.0%) 3 (37.5%) - -
Four drug regimen and isoniazid resistance, N = 7 7 (100%)
Extrathoracic TB N = 199 53 (26.6%) 34 (17.1%) 57 (28.7%) 44 (22.1%) 11 (5.5%)
Meningeal, N = 7 2 (28.6%) 0 2 (28.6%) 3 (42.8%) -
Isolated nodal, N = 98 34 (34.7%) 18 (18.4%) 29 (29.5%) 13 (13.3%) 4 (4.1%)
Isolated osteoarticular, N = 22 2 (9.1%) 2 (9.1%) 6 (27.3%) 9 (40.9%) 3 (13.6%)
Disseminated or military, N = 41 6 (14.6%) 4 (9.8%) 11 (26.8%) 16 (39.0%) 4 (9.8%)
Other, N = 31 9 (29.0%) 10 (32.3%) 9 (29.0%) 3 (9.7%) -
Abnormally lengthy treatments are in bold.
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dependent adverse effects, including peripheral neuropa-
thies and liver toxicity, especially in patients with under-
lying liver disease[9,10]. Moreover, prolonged treatment
can have a negative impact on patient adherence,[10]
thereby increasing the risk of selecting resistant strains.
The reasons for these deviations from official recom-
mendations are unclear. In France, possible reasons
include the general tendency to overuse antiinfectives,
the fear of not eradicating a potentially life-threatening
infection, the fear of relapse, the incorrect belief that
extrapulmonary TB is more difficult to treat than pul-
monary TB, and simple unawareness of practice guide-
lines[3]. In our study, cases of MDR-TB cases were
excluded, but drug susceptibility testing results were not
available for nine patients who might therefore have
been infected with MDR-TB, and the weight of these
patients in the analysis results may be of concern. How-
ever, multivariate analysis excluding these nine patients
yielded similar results, with the same variables remain-
ing significant. When a control sputum smear is positive
at the end of the intensive treatment phase, treatment
prolongation might be warranted. However, French
guidelines do not recommend such smear controls,
except in the case of MDR-TB or if symptoms persist or
reappear[7]. In our study, analysis of the medical reports
confirmed that the practitioners had not prescribed such
control smears. We found that infectious disease specia-
lists were more likely than chest specialists to prescribe
excessively long treatment, and that HIV-seropositive
patients were also more likely to be prescribed exces-
sively lengthy treatment (Table 1). WHO 2003 guide-
lines and French guidelines and previous studies
recommended that TB patients living with HIV should
receive the same TB treatment duration as HIV-serone-
gative patients[5-7,11]. However, infectious disease spe-
cialists often prefer to treat longer than recommended
because they consider their patients more vulnerable,
owing to their immunodepression and the relatively
high frequency of disseminated TB and severe inflam-
matory forms[12]. A recent retrospective study of HIV-
seropositive TB patients showed that those receiving a
six-month course of treatment had a higher risk of
relapse than patients treated for longer periods[13]. Cur-
rent (i.e. 2010) WHO guidelines specify that some
experts recommend prolonging TB treatment for per-
sons living with HIV[14]. Therefore, the excessively long
treatment of HIV-infected patients in our study prob-
ably reflects the evolution of practices and guidelines.
A prior history of TB was also associated with exces-
sively lengthy treatment (Table 1), even though a six-
month course is considered adequate for patients with
fully sensitive strains[3]. Excessively lengthy treatment was
more frequent among patients with isolated thoracic TB
than among those with extrathoracic TB, but we found
that a substantial number of patients with extrathoracic
TB due to sensitive strains were treated for more than 12
months, conflicting with international guidelines and pub-
lished data[5-7]. We did not consider a 12-month course
excessive for extra-pulmonary TB, as international guide-
lines specify that “treatment can be prolonged to 9 or 12
months in case of severe extrapulmonary or neuromenin-
geal TB”[7]. However, contemporary French guidelines did
not recommend special treatment for patients with extra-
thoracic forms[7]. Assuming that 6 months of treatment is
adequate for all forms of extra-pulmonary TB, with the
exception of neuromeningeal TB, more than half of the
patients with nodal, osteaoarticular and disseminated
forms received excessively long treatment in our study.
Similar results have been obtained elsewhere,[2] calling for
better training of prescribers or, alternatively, for treat-
ment of these forms solely in specialized centers.
Patients who were managed in several healthcare
structures were more likely to receive excessively long
therapy. As the date of treatment initiation may not
always be available for the second or third practitioner
dealing with a given patient, these practitioners may
prefer to err on the side of excessively long therapy.
Centralized computer records for use by all national
healthcare structures might improve the quality and
conformity of patient care. Indeed, in a pediatric study,
the use of computers improved the recording and com-
pliance of management plans, although doctors found
the system “too tedious to use during routine care”[15].
In France, such software has been shown to improve TB
patient care and to reduce losses to follow-up[16,17].
To our knowledge, ours is the first study to analyze
determinants of excessively lengthy TB treatment in a
low-incident country. Most previous studies of TB
patient management focused on patient-related factors
involved in excessively short treatment, such as alcohol
dependence, drug use, and precarious living conditions
[18-20]. Our findings show that excessively lengthy
treatments are mainly associated with patient manage-
ment modalities. This is also the first study to examine
actual treatment periods based on patients’ medical
reports rather than on an audit of physician practices[3].
This study is limited by its retrospective nature,
including the fact that some patients were excluded
because their files could not be found despite an exten-
sive archive search. The study was conducted solely in
the eastern Paris region, and included five of the French
teaching hospitals that notify the largest number of TB
cases (between 50 and 100 per year). Management prac-
tices might be somewhat different in smaller healthcare
structures. However, it has been reported that physicians
who treat few TB patients are less likely to be aware of
TB management guidelines and that they tend to treat
TB for far longer periods[21].
Valin et al. BMC Public Health 2010, 10:495
http://www.biomedcentral.com/1471-2458/10/495
Page 5 of 6
Conclusion
This study shows that one-third of TB patients received
excessively lengthy treatment in 2004 in the eastern
Paris region of France. These results call for programs
to improve physician awareness of TB management
guidelines and to improve adherence to these guidelines,
especially with respect to HIV-seropositive patients. A
national tuberculosis control program launched in
France in July 2007 aimed at proposing control strate-
gies. In particular, monitoring of the treatment duration
is expected to result in more appropriate treatment peri-
ods, in keeping with current guidelines[22]. Further eva-
luation of such data should allow us to detect the
changes that have occurred since 2004.
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